The Moonshot program was established in the UK by The Department of Health and Social Care to explore novel technologies for the detection of SARS-COV-2. Mass spectrometry was identified as a potential candidate and experts from academia, industry and the National Health Service (NHS) worked in partnership to develop a state-of-the-art targeted proteomic assay, refine the method for use in a routine clinical environment, and validate it to ISO:15189 standards.
Learning Objectives:
1. Demonstration of an LC-MS/MS workflow for the analysis of SARS-CoV-2, with excellent agreement to PCR.
2. Validation of a ready to use SARS-CoV-2 LC-MS Kit, automated on the Andrew Alliance Andrew+ pipetting robot.
3. Differentiation of the SARS-CoV-2 delta variant from previous variants of concern.